Quinupristin/dalfopristin in Staphylococcus aureus endophthalmitis: a case report
© Hernandez-Da Mota; licensee BioMed Central Ltd. 2011
Received: 12 January 2010
Accepted: 31 March 2011
Published: 31 March 2011
The intravitreal injection of antibiotics remains the mainstay of therapy for postoperative endophthalmitis. Bacterial resistance, however, is still a pitfall in achieving an adequate response to treatment. Quinupristin/dalfopristin might be a feasible therapeutic option in these cases.
A 55-year-old Hispanic man had endophthalmitis secondary to Staphylococcus aureus in his right eye and was treated with intravitreal 0.4 mg/0.1 ml quinupristin/dalfopristin injection. Inflammation and pain remission were observed at four days after injection. The final best-corrected visual acuity was 20/40.
Although vancomycin remains the first-line intravitreal antibiotic therapy against infectious endophthalmitis caused by Gram-positive bacteria, quinupristin/dalfopristin exhibits similar efficacy and is theoretically more active against vancomycin-resistant strains, with no apparent retinal toxicity.
Postoperative endophthalmitis has been a major and dreaded complication in all types of eye surgery. Several measures have been used for its prevention, such as aseptic techniques and topical prophylactic antibiotics. Although these measures have resulted in very low endophthalmitis incidence , they have not been able to eliminate it completely.
Once infection is identified, the mainstay of therapy has been the intravitreal injection of antibiotics . The concomitant use of pars plana vitrectomy and steroids has also been recommended  in some cases.
The most common bacterial etiology of the disease involves Gram-positive bacteria, especially Staphylococci. Vancomycin, a glucopeptide antibiotic, has shown adequate activity against this type of bacteria .
Nonetheless, as with all kinds of antibiotics, resistance that could preclude a favorable outcome in these patients may emerge .
Quinupristin/dalfopristin (Q/D), a recently developed streptogramin antibiotic, has shown better activity against vancomycin-resistant strains of staphylococci .
The purpose of this report is to describe a case in which intravitreal quinupristin/dalfopristin injection in endophthalmitis due to Staphylococcus sp. resulted in remission of the infection.
A 55-year-old Hispanic man, in whom non-complicated phacoemulsification surgery had been performed in the right eye, exhibited a sudden decrease in visual acuity, intense pain, and marked red eye two days later.
B-scan echography showed increased intravitreal echoes due to the severe inflammatory reaction. A pars plana vitrectomy was performed, and a vitreous biopsy specimen was obtained. A combination of quinupristin/dalfopristin (0.4 mg/0.1 ml; Synercid; DSM Pharmaceuticals, Inc., Greenville, NC), ceftazidime (2.25 mg/0.1 ml) (Fortum; GlaxoSmithKline, Mexico DF, Mexico), and dexamethasone (0.4 mg/0.1 ml) (Alin, Chinoin, Mexico DF, Mexico) was injected intravitreally.
A coagulase-negative Staphylococcus aureus strain that was vancomycin resistant was identified through culture analysis.
Infectious endophthalmitis treatment has evolved with time. The condition was a common complication in the pre-Listerian era and the cause of many disastrous outcomes in intraocular surgery.
Now, although uncommon, endophthalmitis remains one of the most feared complications of intraocular surgery . The gold standard of treatment has been the intravitreal administration  of antibiotics over topical, subconjunctival, or systemic routes.
Several modifications have been made to the combination of antibiotics given intravitreally before the causative agent is known. These modifications are mainly based on retinal toxicity and bacterial susceptibility to different antibiotics. The combination of antibiotics that is currently preferred empirically includes vancomycin and ceftazidime.
Vancomycin is a glucopeptide antibiotic that is active against Gram-positive bacteria . Ceftazidime, a third-generation cephalosporine, is active against Gram-negative bacteria, especially enterobacteria.
Although vancomycin has not been overused and is reserved as a third-line antibiotic against serious infections (for example, sepsis), certain staphylococci strains have developed resistance . This could be a potential source of therapeutic failure in some cases of endophthalmitis.
Q/D is a combination of two streptogramins: quinupristin (a B streptogramin) and dalfopristin (an A streptogramin) at a 30:70 ratio, respectively. The combination acts as a rapid bactericide, except for its action against Enterococcus faecium, which is less. The combination has a prolonged antibiotic effect (up to 10 hours) for Staphylococcus aureus compared with other antibiotics. Its spectrum of coverage includes Gram-positive cocci, including strains that are resistant to other antibiotics. Methicillin-sensitive and resistant strains of Staphylococcus aureus are also covered by Q/D.
The minimal inhibitory concentrations are 1 mg/ml or less. To the best of our knowledge, no reports of ocular toxicity exist . Given this excellent anti-staphylococcal profile, the absence of ocular toxicity reports, the prolonged antibacterial effects, and the fact that no vancomycin was available at the time, we decided to treat the patient with the antibiotic combination described. Q/D, conversely, is a more recent antibiotic, which, theoretically, is less likely to induce the development of resistant strains than is vancomycin. The pharmacokinetics and pharmacodynamics of intravitreal Q/D have not yet been studied.
Our patient exhibited an adequate response to the use of intravitreal Q/D that was documented four days after injection. This response is similar to that shown to vancomycin. Notably, the use of the combination carries with it the potential advantage that we could be fighting strains that are resistant to vancomycin. Moreover, a synergistic effect of the vancomycin-quinupristin/dalfopristin combination has been documented against some Gram-positive bacteria . We believe that the favorable outcome in our patient was achieved, in order of decreasing importance, by the following factors: 1) Q/D; 2) vitrectomy, which removed infected vitreous strands; and 3) dexamethasone, which limited the severity of inflammation. Ceftazidime affects mainly Gram-negative bacteria, so it probably did not play an important role in controlling the infection process.
Another issue that should be addressed is the fact that Q/D is an expensive medication, and its cost may outweigh its benefit. Moreover, the intravitreal route of this antibiotic is off-label for infectious endophthalmitis.
In conclusion, Q/D showed a positive outcome in this case of infectious postoperative endophthalmitis caused by Gram-positive bacteria. To the best of our knowledge, this is the first report on the use of intravitreal quinupristin/dalfopristin in infectious Staphylococcus endophthalmitis. This report does not recommend Q/D as a first-line choice for conventional treatment of infectious endophthalmitis. Rather, we describe a positive outcome in one case.
I write the following to provide assistance to the case report written about my operation. I have no medical knowledge or background, so I only write from my own perspective and experience. I arrived at the hospital with severe eye pain and completely blurred vision in my right eye a few days after my cataract surgery. I then was told that a very bad infection had taken over my eye. I was told that one of the specific antibiotics for this type of infection was not available, but that a non-approved one could be of benefit, so I agreed to be treated with the non-approved antibiotic via eye injection, in combination with other drugs as well as a vitrectomy surgery, which was performed subsequently. A few hours later, the pain slowly decreased until I did not feel it any more. My sight was still blurred for about a month and a half, but it slowly came back. I still see some little dots, but my vision seems okay now.
Written informed consent was obtained from the patient for the treatment and the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of the journal.
The author acknowledges the support of the staff of Clinica David.
- Allen HF: Symposium: postoperative endophthalmitis: introduction: incidence and etiology. Ophthalmology. 1978, 85: 317-319.View ArticlePubMed
- Baum J, Peyman GA, Barza M: Intravitreal administration of antibiotics in the treatment of bacterial endophthalmitis, III. consensus. Surv Ophthalmol. 1982, 26: 204-206. 10.1016/0039-6257(82)90080-7.View ArticlePubMed
- Endophthalmitis Vitrectomy Study Group: Results of the Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis: Endophthamitis Vitrectomy Study Group. Arch Ophthalmol. 1995, 113: 1479-1496.View Article
- Smith MA, Sorenson JA, D'Aversa G, Mandelbaum S, Udell I, Harrison W: Treatment of methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone. J infect Dis. 1997, 175: 462-466. 10.1093/infdis/175.2.462.View ArticlePubMed
- Juarez-Verdayes MA, Reyes-Lopez MA, Cancino-Diaz ME, Muñoz-Salas S, Rodríguez-Martínez S, de la Serna FJ, Hernández-Rodríguez CH, Cancino-Díaz JC: Isolation, vancomycin resistance and biofilm production of Staphylococcus epidermidis from patients with conjunctivitis, corneal ulcers, and endophthalmitis. Rev Latinoam Microbiol. 2006, 48: 238-246.PubMed
- Finch RG: Antibacterial activity of quinupristin/dalfopristin: rationale for clinical use. Drugs. 1996, 51: 31-37. 10.2165/00003495-199600511-00007.View ArticlePubMed
- Lorian V, Fernandes F: Synergic activity of vancomycin quinupristin/dalfopristin combination against Enterococcus faecium. J Antimicrob Chemother. 1997, 39: 63-66. 10.1093/jac/39.suppl_1.63.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.